Archive · 19 Jan 2026
Syngene Extends Bristol Myers Squibb Collaboration to 2035
Syngene International and Bristol Myers Squibb (BMS) have extended their partnership until 2035.
This means they will work together for another five years to develop new medicines.
Syngene will help BMS with different parts of making medicines, like finding new drugs, testing them, and making them ready for people to use.
They have a special research center called BBRC where 700 scientists work on projects for heart health, immune system diseases, and cancer.
This long-term plan helps both companies build new skills and tools for the future.
Syngene International extends its collaboration with Bristol Myers Squibb (BMS) to 2035.
The partnership expands to include integrated services across the drug development lifecycle.
Syngene's BBRC center houses 700 scientists working on various therapeutic areas.
The collaboration aims to advance innovative science and accelerate medicine delivery.
The partnership began in 1998 and has evolved into a major strategic R&D site for BMS.
- Who
- Syngene International and Bristol Myers Squibb
- What
- Extension of their collaboration agreement to 2035
- When
- January 19, 2026
- Where
- Global, with a focus on the Biocon Bristol Myers Squibb Research and Development Centre (BBRC)
- Why
- To advance innovative science and accelerate the delivery of transformative medicines
- Companies Involved
- Syngene International, Bristol Myers Squibb
- Collaboration Duration
- Extended to 2035
- Services Expanded
- Discovery, translational services, pharmaceutical development, manufacturing, clinical trials, data and IT services
- Strategic Partner
- Syngene as a strategic partner for BMS
- Research Center
- Biocon Bristol Myers Squibb Research and Development Centre (BBRC)
- Scientists at BBRC
- 700 Syngene scientists
- Therapeutic Areas
- Cardiovascular, fibrosis, immunology, oncology
- Collaboration Start Year
- 1998